ASSESSMENT OF A TREATMENT PATHWAY FOR ZOLEDRONIC ACID AFTER HIP FRACTURE

被引：0
|
作者：
Allison, Sara J. [1 ]
Cunliffe, Jonathan [2 ]
May, Philippa R. [2 ]
Abbey, Elizabeth [2 ]
Firth, Miranda [3 ]
Elphick, Heather L. [2 ]
机构：
[1] Sheffield Teaching Hosp NHS Trust, Geriatr & Stroke Med, Sheffield, S Yorkshire, England
[2] Sheffield Teaching Hosp NHS Trust, Trauma & Orthopaed, Sheffield, S Yorkshire, England
[3] Sheffield Teaching Hosp NHS Trust, Metab Bone Ctr, Sheffield, S Yorkshire, England
来源：
OSTEOPOROSIS INTERNATIONAL | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P83
引用
收藏
页码：644 / 644
页数：1
相关论文
共 50 条
  • [1] Zoledronic acid and clinical fractures and mortality after hip fracture
    Lyles, Kenneth W.
    Colon-Emeric, Cathleen S.
    Magaziner, Jay S.
    Adachi, Jonathan D.
    Pieper, Carl F.
    Mautalen, Carlos
    Hyldstrup, Lars
    Recknor, Chris
    Nordsletten, Lars
    Moore, Kathy A.
    Lavecchia, Catherine
    Zhang, Jie
    Mesenbrink, Peter
    Hodgson, Patricia K.
    Abrams, Ken
    Orloff, John J.
    Horowitz, Zebulun
    Eriksen, Erik Fink
    Boonen, Steven
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (18): : 1799 - 1809
  • [2] Zoledronic acid, clinical fractures and mortality after hip fracture
    Baminger, Helmut
    [J]. JOURNAL FUR MINERALSTOFFWECHSEL, 2009, 16 (01): : 56 - 56
  • [3] Potential Mediators of the Reduction in Mortality with Zoledronic Acid after Hip Fracture
    Colon-Emeric, C.
    Mesenbrink, P.
    Lyles, K.
    Pieper, C.
    Boonen, S.
    Delmas, P.
    Eriksen, E.
    Magaziner, J.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2008, 23 : S10 - S10
  • [4] Potential Mediators of the Mortality Reduction With Zoledronic Acid After Hip Fracture
    Colon-Emeric, Cathleen S.
    Mesenbrink, Peter
    Lyles, Kenneth W.
    Pieper, Carl F.
    Boonen, Steven
    Delmas, Pierre
    Eriksen, Erik F.
    Magaziner, Jay
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2010, 25 (01) : 91 - 97
  • [5] Denosumab versus zoledronic acid in elderly patients after hip fracture
    Kim, Seung-Ju
    Kim, Ji Woon
    Lee, Dong-Woo
    [J]. JOURNAL OF ORTHOPAEDIC SURGERY, 2022, 30 (03)
  • [6] Is it safe? IV Zoledronic Acid when given early after hip fracture
    Mahon, James
    Hannigan, Oisin
    McCarroll, Kevin
    Casey, Miriam
    Walsh, J. B.
    [J]. AUSTRALASIAN JOURNAL ON AGEING, 2021, 40 : 79 - 80
  • [7] USE OF ZOLEDRONIC ACID IN REDUCING CLINICAL FRACTURES AND MORTALITY AFTER HIP FRACTURE
    Zidrou, C.
    Alvanos, D.
    Neophytou, D.
    Kyriakidis, T.
    Kyriakidis, A.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2010, 21 : 200 - 200
  • [8] Zoledronic acid for hip fracture during initial hospitalization
    Fan, Wuqiang
    Sun, Xiaoxu
    Leder, Benjamin Z.
    Lee, Hang
    Ly, Thuan, V
    Pu, Charles T.
    Franco-Garcia, Esteban
    Bolster, Marcy B.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2024, 39 (08) : 1061 - 1070
  • [9] Zoledronic acid reduces recurrent clinical fracture in patients with hip fracture
    Stuart L. Silverman
    [J]. Current Osteoporosis Reports, 2009, 7 (1) : 1 - 2
  • [10] Subgroup Variations in Bone Mineral Density Response to Zoledronic Acid After Hip Fracture
    Magaziner, Jay S.
    Orwig, Denise L.
    Lyles, Kenneth W.
    Nordsletten, Lars
    Boonen, Steven
    Adachi, Jonathan D.
    Recknor, Chris
    Colon-Emeric, Cathleen S.
    Mesenbrink, Peter
    Bucci-Rechtweg, Christina
    Su, Guoqin
    Johnson, Rasheeda
    Pieper, Carl F.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2014, 29 (12) : 2545 - 2551
12345